Living & Coping with AIDS-Related Lymphoma: Integrating Antiretroviral Therapy (ART) with Oncology Care, Managing Treatment Side Effects, Preventing Infections, and Emotional Resilience
A chronic care guide on continuing antiretroviral therapy through chemotherapy, immune monitoring, R-CHOP and immunotherapy, prophylactic medicines, neutropenic precautions, fatigue, and dual-diagnosis support.
Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026
Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.
What we found that needs correcting
- This guide gets the core principle right, and it is the one that changed outcomes in this disease: antiretroviral therapy continues alongside chemotherapy rather than being paused. The notes below are led by two safety specifics that the guide gestures at without naming, both of which are decided in the first days.
- The guide says the care team will check drug-drug interactions, and the specifics matter enough to state. Ritonavir and cobicistat, the boosters used with some antiretrovirals, strongly inhibit CYP3A4, the same enzyme that clears vincristine, doxorubicin, etoposide and cyclophosphamide. Blocking it raises those drug levels substantially, and with vincristine this causes severe neuropathy and has caused serious harm. Standard practice is to switch to an unboosted regimen, usually integrase inhibitor-based, before chemotherapy starts. Zidovudine is also avoided because it suppresses the marrow on top of the chemotherapy.
- Hepatitis B screening before rituximab is missing and is a preventable cause of death. Rituximab depletes B-cells and can reactivate hepatitis B in anyone ever infected, including people whose infection appeared resolved. Screening requires surface antigen and core antibody, and where either is positive, antiviral prophylaxis is given through treatment and afterwards. Hepatitis B co-infection is considerably more common in HIV than in the general population.
- A fever during neutropenia is a medical emergency and the guide never says so. A single temperature of 38.3 C (101 F), or 38.0 C (100.4 F) for an hour, means going in immediately at any hour, with the goal of intravenous antibiotics within an hour of arrival, and not taking paracetamol first because it masks the signal. The neutropenic precautions listed are good and this is what to do when they fail. Breathlessness with a dry cough warrants particular urgency here because of Pneumocystis.
- Two points on the precautions themselves. The strict neutropenic diet that removes all fresh fruit and vegetables has been tested against ordinary food safety guidance and has not been shown to reduce infection, while reducing intake when calories are already hard to maintain. And no rectal thermometers, suppositories or enemas while neutropenic, which is a standard caution the guide omits.
- Prophylaxis stops on the CD4 count, not on the chemotherapy calendar, and this is routinely misunderstood. Pneumocystis prophylaxis continues until counts have recovered and stayed up, which takes months after treatment ends. Stopping when the last cycle finishes is a recognized route to a preventable infection.
- Fertility preservation is absent and is time-critical. Chemotherapy can cause permanent infertility, and sperm banking, egg or embryo freezing have to be arranged before treatment begins.
- The treatment description could be updated. Dose-adjusted EPOCH with rituximab is commonly used for HIV-associated large B-cell lymphoma rather than R-CHOP alone; central nervous system prophylaxis with intrathecal chemotherapy is given in Burkitt and higher-risk cases; tumour lysis syndrome is a particular hazard in Burkitt lymphoma and is pre-empted with fluids and allopurinol or rasburicase; and growth factor support such as filgrastim is used routinely. Treatment is now given at full dose, and reducing doses because of HIV is associated with worse outcomes.
- On fatigue, the guide recommends short daily walks and extended rest. Both are right, and the evidence is stronger than the wording suggests: across many trials, exercise reduces cancer-related fatigue more reliably than any drug tested for it. It is also worth checking the treatable contributors first, including anaemia, thyroid function, depression and sedating medicines.
- Relapse options should be mentioned in a survivorship section, because people assume there are none. Second-line chemotherapy, autologous stem cell transplant and CAR-T therapy are all used in people with HIV, and HIV status alone is no longer a barrier to any of them.
- Two additions to survivorship: routine surveillance scanning in people in remission is no longer recommended in most settings, because most relapses are found through symptoms, which changes what people should report between appointments; and a revaccination plan is needed after rituximab, with live vaccines deferred until immune recovery.
- One thing the guide could say more loudly, because it is true and people arrive not believing it: with modern antiretroviral therapy and full-dose chemotherapy, outcomes in HIV-associated lymphoma now approach those of people without HIV, and most people treated are cured.
- Everything else in the guide is accurate: simultaneous management of HIV and lymphoma with coordinated oncology and infectious disease care; maintaining viral suppression to preserve immune function and tolerance; regular CD4 and viral load monitoring guiding supportive care and prophylaxis; prophylactic antibiotics, antifungals and antivirals against opportunistic infections including Pneumocystis; handwashing, avoiding crowds, respirator use and safe food handling during low counts; pacing with walks and rest for fatigue and anaemia; oncology social workers, HIV peer navigators and mental health counselors who understand both fields; dual-diagnosis support networks reducing isolation; and survivorship care plans with ongoing oncologic surveillance.
Download the PDF
Our reviewed pages on this
All source documents